DE69329030D1 - Antigen enthaltende mikropartikel und ihre verwendung für die induzierung von humoralen oder zellulären antworten - Google Patents
Antigen enthaltende mikropartikel und ihre verwendung für die induzierung von humoralen oder zellulären antwortenInfo
- Publication number
- DE69329030D1 DE69329030D1 DE69329030T DE69329030T DE69329030D1 DE 69329030 D1 DE69329030 D1 DE 69329030D1 DE 69329030 T DE69329030 T DE 69329030T DE 69329030 T DE69329030 T DE 69329030T DE 69329030 D1 DE69329030 D1 DE 69329030D1
- Authority
- DE
- Germany
- Prior art keywords
- pct
- cellular
- induction
- answers
- microparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011859 microparticle Substances 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000001413 cellular effect Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 230000006698 induction Effects 0.000 abstract 3
- 230000036755 cellular response Effects 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000008348 humoral response Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/918—Immunological
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9210879A FR2695563B1 (fr) | 1992-09-11 | 1992-09-11 | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
PCT/FR1993/000876 WO1994006472A1 (fr) | 1992-09-11 | 1993-09-13 | Microparticules portant des antigenes et leur utilisation pour l'induction de reponses humorales ou cellulaires |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69329030D1 true DE69329030D1 (de) | 2000-08-17 |
DE69329030T2 DE69329030T2 (de) | 2001-03-22 |
Family
ID=9433435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69329030T Expired - Lifetime DE69329030T2 (de) | 1992-09-11 | 1993-09-13 | Antigen enthaltende mikropartikel und ihre verwendung für die induzierung von humoralen oder zellulären antworten |
Country Status (12)
Country | Link |
---|---|
US (1) | US5871747A (de) |
EP (1) | EP0662000B1 (de) |
AT (1) | ATE194496T1 (de) |
AU (1) | AU4966693A (de) |
CA (1) | CA2144425C (de) |
DE (1) | DE69329030T2 (de) |
DK (1) | DK0662000T3 (de) |
ES (1) | ES2149210T3 (de) |
FR (1) | FR2695563B1 (de) |
GR (1) | GR3034550T3 (de) |
PT (1) | PT662000E (de) |
WO (1) | WO1994006472A1 (de) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4313975A1 (de) * | 1993-04-28 | 1994-11-03 | Cytech Biomedical Inc | Immunisierungsmittel und Affinitätschromatographie-Trägermaterial |
CN1120809A (zh) * | 1993-12-23 | 1996-04-17 | Gff工业方向促进研究公司 | 增强免疫应答的方法 |
ES2108614B1 (es) * | 1995-07-12 | 1998-07-16 | Oncina Fco Javier Martin | Vacunas polimerizadas. |
US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
US20040202680A1 (en) * | 1997-01-30 | 2004-10-14 | O'hagan Derek | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
NZ337054A (en) * | 1997-01-30 | 2001-03-30 | Chiron Corp | Microparticles PLA and PLG with adsorbed viral antigen to stimulate immune responses particularly for intracellular viruses such as HSV-1 or HSV-2, varicella zoster virus. epstein-barr virus or cytomegalovirus (CMV) |
EP0973873B1 (de) * | 1997-04-08 | 2006-06-07 | Pall Corporation | Verfahren zur gewinnung von seltenen zellen aus blutprodukten |
US7731972B1 (en) | 2000-02-04 | 2010-06-08 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Immunoprotective influenza antigen and its use in vaccination |
AU745951B2 (en) | 1997-08-05 | 2002-04-11 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | New immunoprotective influenza antigen and its use in vaccination |
US7087236B1 (en) * | 1998-09-01 | 2006-08-08 | Merrion Research I Limited | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
US8236352B2 (en) * | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
WO2000032227A2 (en) * | 1998-11-30 | 2000-06-08 | Cytos Biotechnology Ag | Ordered molecular presentation of antigens, method of preparation and use |
AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
JP2003523721A (ja) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性hivc型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
ES2299276T3 (es) * | 1998-12-31 | 2008-05-16 | Novartis Vaccines And Diagnostics, Inc. | Polipeptidos env del vih modificados. |
US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
US20090104273A1 (en) * | 1999-06-22 | 2009-04-23 | Elan Pharma International Ltd. | Novel nifedipine compositions |
US20020009466A1 (en) * | 1999-08-31 | 2002-01-24 | David J. Brayden | Oral vaccine compositions |
US6929907B2 (en) | 1999-12-31 | 2005-08-16 | North Carolina State University | Methods and compositions for determining the purity of chemically synthesized nucleic acids |
WO2001079300A1 (en) * | 2000-04-12 | 2001-10-25 | Genetics Institute, Llc. | Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor |
WO2001085208A2 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
US20040022814A1 (en) * | 2000-06-15 | 2004-02-05 | O'hagan Derek | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
AUPR011700A0 (en) | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
US7198795B2 (en) * | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
CA2420621C (en) | 2000-09-28 | 2011-05-24 | Chiron Corporation | Microparticle compositions and methods for the manufacture thereof |
CN1468089B (zh) * | 2000-09-28 | 2011-09-21 | 诺华疫苗和诊断公司 | 用于传送异源核酸的微粒体 |
US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US20040126900A1 (en) * | 2001-04-13 | 2004-07-01 | Barry Stephen E | High affinity peptide- containing nanoparticles |
US6887857B2 (en) | 2001-04-27 | 2005-05-03 | Scimed Life Systems, Inc. | Microparticle protection of therapeutic agents |
ATE514083T1 (de) * | 2001-06-29 | 2011-07-15 | Veri Q Inc | Verfahren und zusammensetzungen zur reinheitsbestimmung und reinigung chemisch synthetisierter nukleinsäuren |
US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
EP2280074A3 (de) * | 2001-07-05 | 2011-06-22 | Novartis Vaccines and Diagnostics, Inc. | Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen |
FR2828648A1 (fr) * | 2001-08-16 | 2003-02-21 | Adam Bouaziz | Constitution d'un vaccin extractible a partir d'un insert immunogene. |
CA2458995C (en) * | 2001-08-31 | 2013-04-30 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
AU2002347404A1 (en) * | 2001-09-14 | 2003-04-01 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
ES2335979T3 (es) | 2001-09-14 | 2010-04-07 | Cytos Biotechnology Ag | Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso. |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
US20030219459A1 (en) * | 2002-01-18 | 2003-11-27 | Cytos Biotechnology Ag | Prion protein carrier-conjugates |
US20040101566A1 (en) * | 2002-02-04 | 2004-05-27 | Elan Pharma International Limited | Novel benzoyl peroxide compositions |
ATE464880T1 (de) | 2002-02-04 | 2010-05-15 | Elan Pharma Int Ltd | Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator |
US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
WO2003080027A1 (en) * | 2002-03-20 | 2003-10-02 | Elan Pharma International, Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
EP1513552B1 (de) * | 2002-06-20 | 2010-12-01 | Cytos Biotechnology AG | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung |
WO2004006959A1 (en) * | 2002-07-16 | 2004-01-22 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
US7138252B2 (en) | 2002-07-17 | 2006-11-21 | Cytos Biotechnology Ag | Molecular antigen arrays |
KR101228376B1 (ko) | 2002-07-18 | 2013-01-31 | 사이토스 바이오테크놀로지 아게 | 합텐-캐리어 컨쥬게이트 및 그의 용도 |
DE60336902D1 (de) | 2002-07-19 | 2011-06-09 | Cytos Biotechnology Ag | Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays |
US20060210588A1 (en) * | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
AU2004224762B2 (en) * | 2003-03-26 | 2009-12-24 | Kuros Us Llc | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
EP2179729B1 (de) * | 2003-06-02 | 2016-07-20 | GlaxoSmithKline Biologicals SA | Immunogene zusammensetzungen auf basis von mikropartikeln, enthaltend ein adsorbiertes toxoid und ein polysaccharid-enthaltendes antigen |
RU2006130006A (ru) * | 2004-01-20 | 2008-02-27 | Цитос Биотехнологи Аг (Ch) | Конъюгаты грелин-носитель |
US9492400B2 (en) * | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
CA2594612A1 (en) | 2005-01-19 | 2006-07-27 | Vaxinnate Corporation | Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response |
WO2007041190A2 (en) * | 2005-09-30 | 2007-04-12 | The University Of Iowa Research Foundation | Polymer-based delivery system for immunotherapy of cancer |
EP1969031B1 (de) | 2005-12-05 | 2009-06-03 | Nitto Denko Corporation | Polyglutamat-aminosäure-konjugate und verfahren |
EP1973608A1 (de) * | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunstimulatorische nukleinsäure-packteilchen zur behandlung von überempfindlichkeit |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
CA2638760A1 (en) | 2006-03-07 | 2007-09-13 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
ES2776100T3 (es) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
CN101573141B (zh) | 2006-05-15 | 2016-05-04 | 麻省理工学院 | 用于功能性颗粒的聚合物 |
SG172696A1 (en) | 2006-06-12 | 2011-07-28 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
WO2007150030A2 (en) * | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
WO2008019142A2 (en) * | 2006-08-04 | 2008-02-14 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
US20100303723A1 (en) * | 2006-11-20 | 2010-12-02 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
US20080181852A1 (en) * | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
WO2008098165A2 (en) | 2007-02-09 | 2008-08-14 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
WO2008124639A2 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Poly (amino acid) targeting moieties |
EP2144631A2 (de) * | 2007-04-10 | 2010-01-20 | Nitto Denko Corporation | Multifunktionale polyglutamat-wirkstoffträger |
DK2155254T3 (da) * | 2007-05-09 | 2013-03-04 | Nitto Denko Corp | Med platinlægemidler konjugerede polymere |
JP2010526917A (ja) * | 2007-05-09 | 2010-08-05 | 日東電工株式会社 | 複数種の薬物を有するポリグルタミン酸塩複合体及びポリグルタミン酸塩−アミノ酸複合体 |
JP5341879B2 (ja) | 2007-05-09 | 2013-11-13 | 日東電工株式会社 | 疎水性化合物及びポリアミノ酸複合体を含む組成物 |
CN105770878A (zh) | 2007-10-12 | 2016-07-20 | 麻省理工学院 | 疫苗纳米技术 |
CN102083468A (zh) * | 2008-03-06 | 2011-06-01 | 日东电工株式会社 | 用于治疗癌症的聚合物紫杉醇结合物和方法 |
AU2009236585B2 (en) | 2008-04-18 | 2013-03-07 | Vaxinnate Corporation | Deletion mutants of flagellin and methods of use |
US20110280930A1 (en) * | 2008-05-02 | 2011-11-17 | Facundo Batista | Products and methods for stimulating an immune response |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
BRPI1011836A2 (pt) * | 2009-04-21 | 2017-05-16 | Selecta Biosciences Inc | imunonanoterapêuticos que fornecem uma resposta induzida por th1 |
EA022699B1 (ru) | 2009-05-27 | 2016-02-29 | Селекта Байосайенсиз, Инк. | НАЦЕЛЕННЫЕ СИНТЕТИЧЕСКИЕ НАНОНОСИТЕЛИ С pH-ЧУВСТВИТЕЛЬНЫМ ВЫСВОБОЖДЕНИЕМ ИММУНОМОДУЛИРУЮЩИХ СРЕДСТВ |
WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CN107029223A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
CA3118108C (en) | 2010-11-12 | 2024-02-20 | Oncour Pharma, Inc. | Modified immune-modulating particles comprising poly(lactic acid) |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
KR20140050698A (ko) | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체 |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
EP2863942B1 (de) | 2012-06-21 | 2019-04-10 | Northwestern University | Peptidkonjugierte teilchen |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
US9913883B2 (en) | 2013-03-13 | 2018-03-13 | Cour Pharmaceuticals Development Company | Immune-modifying nanoparticles for the treatment of inflammatory diseases |
HUE047329T2 (hu) | 2013-08-13 | 2020-04-28 | Univ Northwestern | Peptiddel konjugált részecskék |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (de) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3069730A3 (de) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3303585A4 (de) | 2015-06-03 | 2018-10-31 | Board of Regents of the University of Nebraska | Dna-editierung mit verwendung von einzelstrang-dna |
WO2018031771A1 (en) | 2016-08-11 | 2018-02-15 | University Of Iowa Research Foundation | CATIONIC CaMKII INHIBITING NANOPARTICLES FOR THE TREATMENT OF ALLERGIC ASTHMA |
WO2021076794A1 (en) | 2019-10-15 | 2021-04-22 | Cornell University | Methods for modulating level of expression from gene therapy expression cassette |
EP4045653A1 (de) | 2019-10-16 | 2022-08-24 | Cornell University | Gentherapie für morbus alzheimer |
US20230001017A1 (en) | 2019-10-28 | 2023-01-05 | University Of Lowa Research Foundation | Formulation for delivery of lubricin gene |
JP2023502515A (ja) | 2019-11-25 | 2023-01-24 | コーネル・ユニバーシティー | Apoe遺伝子療法 |
CN115835886A (zh) | 2020-04-23 | 2023-03-21 | 衣阿华大学研究基金会 | Gper蛋白水解靶向嵌合体 |
WO2022040564A1 (en) | 2020-08-21 | 2022-02-24 | University Of Iowa Research Foundation | Cationic nanoparticle adjuvants |
US20230414787A1 (en) | 2020-08-27 | 2023-12-28 | University Of Iowa Research Foundation | Gene knock-out for treatment of glaucoma |
WO2022125963A1 (en) | 2020-12-11 | 2022-06-16 | University Of Iowa Research Foundation | Compositions comprising molecules for cystic fibrosis treatment |
WO2022246280A1 (en) | 2021-05-21 | 2022-11-24 | University Of Iowa Research Foundation | Anti-oxidant containing particles and methods of use |
WO2022271951A1 (en) | 2021-06-23 | 2022-12-29 | University Of Iowa Research Foundation | Sustained release formulations comprising a selective androgen receptor modulator |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK143689C (da) * | 1975-03-20 | 1982-03-15 | J Kreuter | Fremgangsmaade til fremstilling af en adsorberet vaccine |
US4861588A (en) * | 1985-02-05 | 1989-08-29 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
US5008116A (en) * | 1988-11-14 | 1991-04-16 | Frederick Cahn | Immunostimulatory microsphere |
US5178882A (en) * | 1990-06-22 | 1993-01-12 | The Regents Of The University Of California | Viral decoy vaccine |
-
1992
- 1992-09-11 FR FR9210879A patent/FR2695563B1/fr not_active Expired - Lifetime
-
1993
- 1993-09-13 CA CA002144425A patent/CA2144425C/fr not_active Expired - Lifetime
- 1993-09-13 EP EP93919446A patent/EP0662000B1/de not_active Expired - Lifetime
- 1993-09-13 AT AT93919446T patent/ATE194496T1/de active
- 1993-09-13 WO PCT/FR1993/000876 patent/WO1994006472A1/fr active IP Right Grant
- 1993-09-13 PT PT93919446T patent/PT662000E/pt unknown
- 1993-09-13 DK DK93919446T patent/DK0662000T3/da active
- 1993-09-13 DE DE69329030T patent/DE69329030T2/de not_active Expired - Lifetime
- 1993-09-13 US US08/397,286 patent/US5871747A/en not_active Expired - Lifetime
- 1993-09-13 AU AU49666/93A patent/AU4966693A/en not_active Abandoned
- 1993-09-13 ES ES93919446T patent/ES2149210T3/es not_active Expired - Lifetime
-
2000
- 2000-10-04 GR GR20000402240T patent/GR3034550T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
US5871747A (en) | 1999-02-16 |
EP0662000B1 (de) | 2000-07-12 |
EP0662000A1 (de) | 1995-07-12 |
DE69329030T2 (de) | 2001-03-22 |
FR2695563B1 (fr) | 1994-12-02 |
FR2695563A1 (fr) | 1994-03-18 |
WO1994006472A1 (fr) | 1994-03-31 |
ATE194496T1 (de) | 2000-07-15 |
PT662000E (pt) | 2000-12-29 |
DK0662000T3 (da) | 2000-11-13 |
AU4966693A (en) | 1994-04-12 |
GR3034550T3 (en) | 2001-01-31 |
ES2149210T3 (es) | 2000-11-01 |
CA2144425C (fr) | 2008-12-30 |
CA2144425A1 (fr) | 1994-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69329030D1 (de) | Antigen enthaltende mikropartikel und ihre verwendung für die induzierung von humoralen oder zellulären antworten | |
ATE163195T1 (de) | Lösliche liganden für cd40 | |
ATE47155T1 (de) | Monoklonaler antikoerper. | |
TR199900666T2 (xx) | �nsan paratormonu ile ilgili peptidlere kar�� antikor. | |
DE69626132T2 (de) | Regulierung von essgewohnheiten | |
DE69632625D1 (de) | Mykrobakterielle proteine, mikroorganismen welche diese produzieren und ihre verwendung als impfstoff und zum nachweis von zuberkulose | |
ATE262537T1 (de) | Proliferationsinhibitor von endothellzellen und dessen verwendung | |
DK0754229T3 (da) | Afamin: et humant serum albumin-lignende protein | |
FI973484A (fi) | Menetelmä immuunivasteen stimuloimiseksi | |
TW272197B (de) | ||
ATE214399T1 (de) | Mycobacteriumprotein und dessen verwendung | |
ATE160359T1 (de) | Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen. | |
ATE175422T1 (de) | Schweineadipozytenantigene und ihre verwendung zur immunologischen kontrolle von fett |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |